Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 4, 2018--Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that data from the TRCA-301 Phase 3 clinical trial of TRC101 will be presented at Kidney Week 2018, the annual meeting of the American Society of Nephrology (ASN). The clinical trial data will be shared, as indicated below, in a late-breaking clinical trials poster presentation at the meeting, being held October 23 to 28 in San Diego, CA:
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully completed a pivotal Phase 3, double-blind, placebo-controlled trial of its product candidate, TRC101, in CKD patients with metabolic acidosis. The results of this Phase 3 trial, along with results from a successful double-blind, randomized, placebo-controlled Phase 1/2 trial and an ongoing safety extension trial, TRCA-301E, are intended to serve as the basis for the submission of an NDA for TRC101 under the FDA’s Accelerated Approval Program.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including for example, the ability of our drug candidate to provide benefit to patients and our ability to submit an NDA for TRC101 under the FDA’s Accelerated Approval Program. Forward‐looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs; there can be no assurance that the FDA would approve an NDA under the Accelerated Approval Program or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; and that there will not be possible safety and efficacy concerns. The forward-looking statements contained in this press release reflect Tricida’s current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005818/en/
CONTACT: Tricida, Inc.
Jackie Cossmon, IRC
Vice President of Investor Relations and Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Tricida, Inc.
Copyright Business Wire 2018.
PUB: 10/04/2018 04:26 PM/DISC: 10/04/2018 04:26 PM